distribute its proven poly herbal ayurvedic drug AYUSH 64 and Siddha medicine Kabasura Kudineer for the benefit of Covid patients in home isolation.
in its statement
A comprehensive strategy of distribution has been sketched out and the role out will unfold in a phased manner, utilizing the wide network of various institutions working under the aegis of the ministry and this will be supported by the countrywide network of Sewa Bharati, the statement said.
“With the latest initiative of the ministry to launch a nationwide campaign for distribution of AYUSH-64 and Kabasura Kudineer, India aims to strengthen its position in fight against Covid19 pandemic”, it said
Many clinical and observational studies have been undertaken to understand the role of Ayush interventions in mitigation and management of Covid 19 where various studies were carried out on AYUSH-64, an Ayurvedic formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS) and Kabasura Kudineer, a classical Siddha formulation.
Kabasura Kudineer was also subjected to clinical trials for studying the efficacy in Covid-19 patients by Central Council for Research in Siddha (CCRS) under ministry of Ayush and is also found useful in the treatment of mild to moderate Covid 19 infection.
Source: The Times of India